Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Ann Oncol 2022; - Tutt, A NJ; Garber, J; Gelber, R D
ESMO Virtual Plenary VP1-2022